Overview
Compare with Pacific Biosciences, Cytek Biosciences, Inc. or Harvard Bioscience, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Simoa Service And Other Revenue brought in 25% of the revenue Quanterix (United States) broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Simoa Service And Other Revenue | $40.1M | $51.2M | $32.4M |
| Research Services | $27.8M | $38.0M | $26.0M |
| Spatial Product Revenue | $0 | $0 | $21.9M |
| Instruments | $15.7M | $10.5M | $17.9M |
| Spatial Service And Other Revenue | $0 | $0 | $11.8M |
| Service-type warranties | $9.9M | $10.6M | $11.1M |
| Other Services | $2.4M | $2.6M | $7.1M |
| License and Service | $1.4M | $4.5M | $1.5M |
| Grant | $1.2M | $2.0M | $243.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue29¢$73.9M
- Research and development14¢$35.9M
- Selling, general and admin55¢$138.0M
- Income tax2¢$5.1M
Out of $138.9M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenues | $138.9M | $137.4M | $122.4M |
| Total costs of goods sold and services | $73.9M | $54.3M | $48.1M |
| Gross profit | $65.0M | $83.1M | $74.2M |
| Research and development | $35.9M | $31.1M | $26.1M |
| Selling, general and administrative | $138.0M | $101.6M | $89.1M |
| Other lease costs | $844.0K | $3.0M | $3.7M |
| Impairment and restructuring | $15.7M | $0 | $1.3M |
| Total operating expenses | $190.5M | $135.7M | $120.2M |
| Loss from operations | -$125.5M | -$52.6M | -$46.0M |
| Interest income | $8.6M | $14.7M | $15.8M |
| Change in fair value of contingent liabilities | -$4.5M | $0 | $0 |
| Other income (expense), net | $157.0K | -$136.0K | $2.5M |
| Loss before income taxes | -$112.3M | -$38.1M | -$27.6M |
| Income tax benefit (expense) | $5.1M | -$434.0K | -$719.0K |
| Net loss | -$107.2M | -$38.5M | -$28.4M |
| Net loss per common share, basic (in dollars per share) | -$2.51 | -$1.00 | -$0.75 |
| Net loss per share, diluted (in dollars per share) | -$2.51 | -$1.00 | -$0.75 |
| Weighted-average common shares outstanding, basic (in shares) | 42.6M shares | 38.4M shares | 37.6M shares |
| Weighted-average common shares outstanding, diluted (in shares) | 42.6M shares | 38.4M shares | 37.6M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $29.8M | $56.7M | ||
| Marketable securities | $88.4M | $232.4M | ||
| Accounts receivable, net of allowance for expected credit losses | $30.0M | $32.1M | ||
| Inventory | $54.8M | $32.8M | ||
| Prepaid expenses and other current assets | $9.3M | $9.6M | ||
| Total current assets | $212.3M | $363.6M | ||
| Restricted cash | $3.3M | $2.6M | ||
| Property and equipment, net | $23.7M | $17.1M | ||
| Intangible assets, net | $131.8M | $4.0M | ||
| Goodwill | $26.4M | $0 | ||
| Operating lease right-of-use assets | $16.7M | $16.3M | ||
| Other non-current assets | $4.7M | $2.8M | ||
| Total assets | $418.8M | $406.5M | ||
| Accounts payable | $13.6M | $7.0M | ||
| Accrued compensation and benefits | $15.0M | $12.6M | ||
| Accrued expenses and other current liabilities | $17.6M | $8.9M | ||
| Deferred revenue | $20.7M | $8.8M | ||
| Operating lease liabilities | $7.9M | $4.8M | ||
| Total current liabilities | $74.8M | $42.0M | ||
| Deferred revenue, net of current portion | $5.8M | $1.1M | ||
| Operating lease liabilities, net of current portion | $29.3M | $32.6M | ||
| Non-current portion of contingent liabilities | $5.0M | $0 | ||
| Other non-current liabilities | $8.1M | $800.0K | ||
| Total liabilities | $123.0M | $76.5M | ||
| Common stock, $0.001 par value per share: Authorized: 120,000 shares; issued and outstanding: 46,744 and 38,573 shares at December 31, 2025 and 2024, respectively | $47.0K | $39.0K | ||
| Additional paid-in capital | $873.6M | $803.2M | ||
| Accumulated other comprehensive loss | -$723.0K | -$3.1M | ||
| Accumulated deficit | -$577.2M | -$470.1M | ||
| Total stockholders equity | $295.7M | $330.0M | $350.0M | $357.9M |
| Total liabilities and stockholders equity | $418.8M | $406.5M | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, authorized shares (in shares) | 120.0M shares | 120.0M shares | ||
| Common stock, shares issued (in shares) | 46.7M shares | 38.6M shares | ||
| Common stock, shares outstanding (in shares) | 46.7M shares | 38.6M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $29.8M | $56.7M | ||
| Marketable securities | $88.4M | $232.4M | ||
| Accounts receivable, net of allowance for expected credit losses | $30.0M | $32.1M | ||
| Inventory | $54.8M | $32.8M | ||
| Prepaid expenses and other current assets | $9.3M | $9.6M | ||
| Total current assets | $212.3M | $363.6M | ||
| Restricted cash | $3.3M | $2.6M | ||
| Property and equipment, net | $23.7M | $17.1M | ||
| Intangible assets, net | $131.8M | $4.0M | ||
| Goodwill | $26.4M | $0 | ||
| Operating lease right-of-use assets | $16.7M | $16.3M | ||
| Other non-current assets | $4.7M | $2.8M | ||
| Total assets | $418.8M | $406.5M | ||
| Accounts payable | $13.6M | $7.0M | ||
| Accrued compensation and benefits | $15.0M | $12.6M | ||
| Accrued expenses and other current liabilities | $17.6M | $8.9M | ||
| Deferred revenue | $20.7M | $8.8M | ||
| Operating lease liabilities | $7.9M | $4.8M | ||
| Total current liabilities | $74.8M | $42.0M | ||
| Deferred revenue, net of current portion | $5.8M | $1.1M | ||
| Operating lease liabilities, net of current portion | $29.3M | $32.6M | ||
| Non-current portion of contingent liabilities | $5.0M | $0 | ||
| Other non-current liabilities | $8.1M | $800.0K | ||
| Total liabilities | $123.0M | $76.5M | ||
| Common stock, $0.001 par value per share: Authorized: 120,000 shares; issued and outstanding: 46,744 and 38,573 shares at December 31, 2025 and 2024, respectively | $47.0K | $39.0K | ||
| Additional paid-in capital | $873.6M | $803.2M | ||
| Accumulated other comprehensive loss | -$723.0K | -$3.1M | ||
| Accumulated deficit | -$577.2M | -$470.1M | ||
| Total stockholders equity | $295.7M | $330.0M | $350.0M | $357.9M |
| Total liabilities and stockholders equity | $418.8M | $406.5M | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, authorized shares (in shares) | 120.0M shares | 120.0M shares | ||
| Common stock, shares issued (in shares) | 46.7M shares | 38.6M shares | ||
| Common stock, shares outstanding (in shares) | 46.7M shares | 38.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$107.2M | -$38.5M | -$28.4M |
| Depreciation and amortization expense | $15.8M | $6.5M | $6.3M |
| Credit losses on accounts receivable | $628.0K | $588.0K | $336.0K |
| Accretion of marketable securities | -$2.1M | -$6.8M | -$2.0M |
| Operating lease right-of-use asset amortization | $3.1M | $1.9M | $2.0M |
| Stock-based compensation expense | $20.7M | $20.0M | $16.8M |
| Impairment | $7.8M | $0 | $1.4M |
| Change in fair value of contingent liabilities | -$4.5M | $0 | $0 |
| Recognition of off-market liability | -$2.7M | $0 | $0 |
| Deferred taxes | -$5.9M | -$290.0K | -$290.0K |
| Other operating activity | -$540.0K | $345.0K | $140.0K |
| Accounts receivable | $10.6M | -$7.7M | -$6.7M |
| Inventory | $4.0M | -$6.7M | -$8.9M |
| Prepaid expenses and other current assets | $3.5M | -$443.0K | -$2.4M |
| Other non-current assets | $252.0K | -$1.2M | -$717.0K |
| Accounts payable | -$528.0K | $723.0K | $1.2M |
| Accrued compensation and benefits, accrued expenses, and other current liabilities | -$7.9M | $1.4M | $4.4M |
| Net change in other operating assets and liabilities | -$12.3M | -$4.9M | -$2.1M |
| Net cash used in operating activities | -$77.2M | -$35.2M | -$18.8M |
| Purchases of marketable debt securities | -$69.8M | -$295.6M | -$175.6M |
| Proceeds from sales and maturities of marketable securities | $215.8M | $216.7M | $31.0M |
| Purchases of property and equipment | -$2.6M | -$3.4M | -$3.8M |
| Acquisitions, net of cash acquired | -$93.2M | $0 | $0 |
| Net cash provided by (used in) investing activities | $50.2M | -$82.3M | -$148.5M |
| Proceeds from common stock issued under stock plans | $738.0K | $3.1M | $2.9M |
| Payments for employee taxes withheld on stock-based compensation awards | -$1.4M | -$2.6M | -$198.0K |
| Net cash provided by (used in) financing activities | -$708.0K | $456.0K | $2.7M |
| Net decrease in cash, cash equivalents, and restricted cash | -$27.7M | -$117.0M | -$164.6M |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | $1.6M | -$734.0K | $301.0K |
| Common stock issued in exchange for acquisition of Akoya | $49.9M | $0 | $0 |
| Purchases of property and equipment in accounts payable and accruals | $121.0K | $1.2M | $419.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Quanterix (United States), and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
- Chief executive officerEverett Cunningham Jan 21, 2026 to now13
- Chief executive officerMasoud Toloue Apr 27, 2022 to Jan 21, 202614
- Chief executive officerE. Kevin Hrusovsky Dec 6, 2017 to Apr 5, 202215
- ChairWilliam P. Donnelly Nov 24, 2025 to now16
- ChairE. Kevin Hrusovsky Aug 9, 2018 to Jul 6, 202217
- PresidentEverett Cunningham Jan 21, 2026 to now13
- PresidentMasoud Toloue Jun 14, 2021 to Jan 21, 202618
- PresidentE. Kevin Hrusovsky Dec 6, 2017 to Sep 3, 202115
- Chief financial officerJason F. Faessler Jun 22, 2026 to now19
- Chief financial officerVandana Sriram Aug 22, 2023 to Jun 22, 202620
- Chief financial officerShawn Stetson May 13, 2021 to May 13, 202121
- Chief financial officerMichael A. Doyle Jul 13, 2021 to Oct 2, 202322
- Chief financial officerAmol Chaubal Apr 15, 2019 to May 5, 202123
- Chief financial officerJoseph Driscoll Dec 6, 2017 to Jan 15, 201924
- Chief operating officerMichael Francis Miller Mar 17, 2026 to now25
- Chief operating officerWilliam Geist Nov 18, 2020 to Feb 10, 202126
Board members and other officers (32)
- Chief Technology OfficerMichael Francis Miller May 18, 2026 to now27
- Chief Commercial OfficerBenjamin Meadows Jun 12, 2026 to now28
- Chief Commercial OfficerJames Edward Gute Jr. Aug 19, 2026 to now29
- Chief Human Resource OfficerAmee Desjourdy Aug 21, 2019 to Aug 21, 201930
- Sr VP, Stgc Mrktg & Assay TechDawn Mattoon Feb 27, 2018 to Apr 5, 202231
- SVP, Corp Dev & StrategyJackson Streeter Nov 14, 2018 to Mar 19, 201932
- VP of Ops, Service and QualityBruce J. Bal Dec 6, 2017 to May 14, 201833
- SVP R&D and CTODavid C. Duffy Dec 6, 2017 to Mar 28, 202234
- SVP Finance and Corporate DevErnest Orticerio Dec 6, 2017 to Jan 11, 201935
- SVP and GM Apps and ReagentsMark T. Roskey Dec 6, 2017 to Apr 5, 202236
- Board memberEverett Cunningham Jan 21, 2026 to now13
- Board memberGoldman Myla Lai Jul 9, 2025 to now37
- Board memberScott Mendel Jul 9, 2025 to now38
- Board memberMalcolm Garret Hampton Nov 25, 2025 to now39
- Board memberAlan Bruce Sachs Dec 8, 2025 to now40
- Board memberJeffrey Thomas Elliott Aug 21, 2024 to now41
- Board memberIvana Magovcevic Oct 3, 2024 to now42
- Board memberBrian J. Blaser Jan 9, 2023 to Jan 4, 202443
- Board memberWilliam P. Donnelly Aug 21, 2023 to now44
- Board memberMasoud Toloue Apr 27, 2022 to now14
- Board memberKaren Flynn Jun 14, 2022 to now45
- Board memberLaurie J. Olson Apr 28, 2021 to May 14, 202446
- Board memberSarah H. McConnell Jul 25, 2019 to now47
- Board memberDavid R. Walt Dec 6, 2017 to now48
- Board memberDouglas G. Cole Dec 6, 2017 to Jan 4, 201949
- Board memberE. Kevin Hrusovsky Dec 6, 2017 to Dec 13, 201715
- Board memberJohn M. Connolly Dec 6, 2017 to Jan 6, 202050
- Board memberKeith Crandell Dec 6, 2017 to Apr 4, 202351
- Board memberMartin D. Madaus Dec 6, 2017 to Jan 6, 202552
- Board memberPaul M. Meister Dec 6, 2017 to now53
- General counselDaniel Char Mar 24, 2026 to now54
- General counselJohn J. Fry Jun 17, 2019 to Aug 3, 202255
Timeline
Filings
541 filings to the SEC since October 2021: 7 annual reports, 17 quarterly reports, 73 major events, 321 insider forms, 45 large holders, 78 other. The latest 20:
- Oct 2, 20264 PRIMARY DOCUMENT EDGAR
- Oct 2, 20264 PRIMARY DOCUMENT EDGAR
- Oct 2, 20264 PRIMARY DOCUMENT EDGAR
- Sep 17, 20264 PRIMARY DOCUMENT EDGAR
- Sep 16, 20264 PRIMARY DOCUMENT EDGAR
- Sep 11, 2026S-8 EDGAR
- Sep 1, 20264 PRIMARY DOCUMENT EDGAR
- Aug 20, 20264 PRIMARY DOCUMENT EDGAR
- Aug 19, 20263 PRIMARY DOCUMENT EDGAR
- Aug 19, 20264 PRIMARY DOCUMENT EDGAR
- Aug 17, 20264 PRIMARY DOCUMENT EDGAR
- Aug 14, 20264 PRIMARY DOCUMENT EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 10, 202610-Q EDGAR
- Aug 10, 20268-K EDGAR
- Aug 6, 2026SCHEDULE 13G EDGAR
- Aug 4, 20264 PRIMARY DOCUMENT EDGAR
- Jul 16, 20264 PRIMARY DOCUMENT EDGAR
- Jul 16, 20264 PRIMARY DOCUMENT EDGAR
- Jul 9, 20264 PRIMARY DOCUMENT EDGAR
The 541 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 45 such filings since October 2021, the latest 10:
- Aug 14, 2026SCHEDULE 13G/A
- Aug 6, 2026SCHEDULE 13G
- May 15, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G/A
- May 7, 2026SCHEDULE 13G/A
- Mar 27, 2026SCHEDULE 13G/A
- Feb 17, 2026SCHEDULE 13G/A
- Nov 19, 2025SCHEDULE 13G
- Nov 14, 2025SCHEDULE 13G/A
- Aug 13, 2025SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| First Eagle Investment Management, LLC | 5,506,330 | $23.8M | 0.0% | +4,206,243 |
| BlackRock, Inc. | 3,635,411 | $15.7M | 0.0% | +357,816 |
| Blue Water Life Science Advisors, LP | 3,474,202 | $15.0M | 9.5% | +1,332,055 |
| Portolan Capital Management, LLC | 1,899,308 | $8.2M | 0.3% | −1,046,515 |
| Vanguard Capital Management LLC | 1,800,644 | $7.8M | 0.0% | +16,031 |
| Lionhunter Capital Management, LLC | 1,500,427 | $6.5M | 2.9% | New |
| Aqr Capital Management LLC | 1,343,005 | $5.8M | 0.0% | +1,258,873 |
| Geode Capital Management, LLC | 1,131,377 | $4.9M | 0.0% | +136,613 |
| Ameriprise Financial Inc | 987,424 | $4.3M | 0.0% | −2,554,950 |
| Marshall Wace, Llp | 973,872 | $4.2M | 0.0% | +351,492 |
| State Street Corp | 932,307 | $4.0M | 0.0% | +34,030 |
| Tikvah Management LLC | 571,555 | $2.5M | 0.8% | −64 |
| Vanguard Portfolio Management LLC | 489,566 | $2.1M | 0.0% | −87,034 |
| Jacobs Levy Equity Management, Inc | 487,600 | $2.1M | 0.0% | New |
| Morgan Stanley | 447,688 | $1.9M | 0.0% | −160,168 |
| Jane Street Group, LLC | 419,050 | $1.8M | 0.0% | +263,395 |
| Tudor Investment Corp Et Al | 400,402 | $1.7M | 0.0% | +84,401 |
| Dimensional Fund Advisors LP | 397,833 | $1.7M | 0.0% | −45,285 |
| Northern Trust Corp | 337,227 | $1.5M | 0.0% | −12,431 |
| Charles Schwab Investment Management Inc | 310,701 | $1.3M | 0.0% | −35,212 |
| Vanguard Fiduciary Trust Co | 288,311 | $1.2M | 0.0% | +17,782 |
| UBS Group AG | 281,978 | $1.2M | 0.0% | −95,004 |
| Nuveen, LLC | 232,592 | $1.0M | 0.0% | +160,750 |
| Citadel Advisors LLC | 229,736 | $992.5K | 0.0% | +168,735 |
| XTX Topco Ltd | 228,035 | $985.1K | 0.0% | +116,375 |
13F reports cover disclosed long positions in U.S. stocks only.
Links
- Websitewww.quanterix.com1
- WikidataQ30265448
- SEC EDGARCIK 1503274
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3Company websiteQuanterix (United States) logo
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARWilliam P. Donnelly, Chair
- 17SEC EDGARE. Kevin Hrusovsky, Chair
- 18SEC EDGARMasoud Toloue, President
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34SEC EDGARDavid C. Duffy, SVP R&D and CTO
- 35
- 36
- 37SEC EDGARGoldman Myla Lai, Board member
- 38SEC EDGARScott Mendel, Board member
- 39SEC EDGARMalcolm Garret Hampton, Board member
- 40SEC EDGARAlan Bruce Sachs, Board member
- 41SEC EDGARJeffrey Thomas Elliott, Board member
- 42SEC EDGARIvana Magovcevic, Board member
- 43SEC EDGARBrian J. Blaser, Board member
- 44SEC EDGARWilliam P. Donnelly, Board member
- 45SEC EDGARKaren Flynn, Board member
- 46SEC EDGARLaurie J. Olson, Board member
- 47SEC EDGARSarah H. McConnell, Board member
- 48SEC EDGARDavid R. Walt, Board member
- 49SEC EDGARDouglas G. Cole, Board member
- 50SEC EDGARJohn M. Connolly, Board member
- 51SEC EDGARKeith Crandell, Board member
- 52SEC EDGARMartin D. Madaus, Board member
- 53SEC EDGARPaul M. Meister, Board member
- 54SEC EDGARDaniel Char, General counsel
- 55SEC EDGARJohn J. Fry, General counsel
